Paragon 28, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
Zimmer Biomet (ZB) and Paragon 28 have entered into a definitive agreement for ZB to acquire Paragon 28, aiming to expand ZB's presence in the foot and ankle segment.
Paragon 28 announces its acquisition by Zimmer Biomet, aiming to enhance its mission to improve surgical outcomes in the foot and ankle market.
Paragon 28 urges shareholders to review proxy statements related to a proposed transaction, highlighting potential risks and benefits while navigating regulatory approvals.
Paragon 28, a foot and ankle care company, has entered into a definitive agreement to be acquired by Zimmer Biomet, a global medical technology leader.
Zimmer Biomet will acquire Paragon 28 for $13.00 per share in cash plus a contingent value right (CVR) payment, potentially reaching a total enterprise value of approximately $1.3 billion.
Zimmer Biomet will acquire Paragon 28 for $13.00 per share in cash, plus a contingent value right, to expand its presence in the foot and ankle orthopedic segment.
DEFA14A: Paragon 28, Inc. Sets Date for 2024 Annual Meeting, Outlines Key Proposals for Stockholder Vote
Paragon 28, Inc. announces its 2024 Annual Meeting of Stockholders to be held on May 17, 2024, featuring proposals including the election of directors, executive compensation, and ratification of the company's independent auditor.
Paragon 28 will hold its 2024 Annual Meeting of Stockholders virtually on May 17, 2024, to vote on director elections, executive compensation, and auditor ratification.